Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation
Journal of Clinical Oncology · 2025
DOI: 10.1200/jco-25-00225 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Panagiotis A Konstantinopoulos und 31 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Ovarian Neoplasms, Cystadenocarcinoma, Serous. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE Patients with platinum-resistant/platinum-refractory high-grade serous ovarian cancer (HGSOC) without a BRCA mutation have poor prognosis and limited treatment options. We report efficacy and biomarker data from EPIK-O, which investigated alpelisib + olaparib versus single-agent chemotherapy in these patients. PATIENTS AND METHODS EPIK-O was an open-label, phase III trial that randomly assigned patients with platinum-resistant/platinum-refractory HGSOC with no germline or known somatic BRCA mutation 1:1 to alpelisib 200 mg once daily + olaparib 200 mg twice daily or treatment of physician's choice (TPC; paclitaxel 80 mg/m 2 once weekly or pegylated liposomal doxorubicin 40-50 mg/m 2 once every 28 days). Patients had 1-3 previous systemic therapies. Previous bevacizumab was required (unless contraindicated); previous poly(adenosine diphosphate-ribose) polymerase inhibitors were allowed. Primary end point was progression-free survival (PFS) per RECIST 1.1 (blinded independent review committee [BIRC]). Secondary efficacy end points included overall response rate (ORR; per BIRC), duration of response (per BIRC), and overall survival (OS; key secondary end point). RESULTS A total of 358 patients (alpelisib + olaparib [n = 180], TPC [n = 178]) were included. The median follow-up time was 9.3 months. At data cutoff (April 21, 2023), 33 (18.3%) and 30 (16.9%) patients remained on treatment with alpelisib + olaparib and TPC, respectively. The median PFS (BIRC) was 3.6 versus 3.9 months (hazard ratio [HR], 1.14 [95% CI, 0.88 to 1.48]; one-sided P = .84) for alpelisib + olaparib versus TPC. The ORR was 15.6% (95% CI, 10.6% to 21.7%) versus 13.5% (95% CI, 8.8% to 19.4%). The median OS was 10.0 versus 10.6 months (HR, 1.22; 95% CI, 0.87 to 1.71). The safety profile of alpelisib + olaparib was consistent with that observed for the individual agents. CONCLUSION The primary objective, PFS improvement, was not met in EPIK-O. No new or unexpected adverse events were observed. Biomarker analyses provided new insights for responders to alpelisib + olaparib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dana-Farber Cancer Institute, Boston, MA.
- Seoul National University, Seoul, South Korea.
- HCL Cancer Institute, Lyon, France.
- GINECO, Paris, France.
- Yonsei Cancer Center and Severance Hospital, Yonsei University, Seoul, South Korea.
- Medical Oncology Department, Hospital Clinic, and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain.
ORCID-Profile: Panagiotis A Konstantinopoulos, Jae Weon Kim, Gilles Freyer, Jung Yun Lee, Lydia Gaba, Nicoletta Colombo, Xiaohua Wu, Felipe Cruz, David Cibula, Bradley J Monk, Michael Friedlander, Domenica Lorusso, Rozita Malik, Christian Marth, Alexandra Leary, Frederik Marmé, Craig Wang, Fei Su, Ursula A Matulonis, Antonio González-Martín
Zitieren
APA
Konstantinopoulos, P. A., Kim, J. W., Freyer, G., Lee, J. Y., Gaba, L., Grisham, R. N., Colombo, N., Wu, X., Sehouli, J., Cruz, F., Cibula, D., Monk, B. J., Nyvang, G. B., Friedlander, M., Lorusso, D., Van Nieuwenhuysen, E., Malik, R., Glasspool, R., Marth, C., …, & González-Martín, A. (2025). Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-00225
Vancouver
Konstantinopoulos PA, Kim JW, Freyer G, Lee JY, Gaba L, Grisham RN, et al. Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation. Journal of Clinical Oncology. 2025. doi:10.1200/jco-25-00225
BibTeX
@article{Konstantinopoulos2025,
author = {Konstantinopoulos, Panagiotis A and Kim, Jae Weon and Freyer, Gilles and Lee, Jung Yun and Gaba, Lydia and Grisham, Rachel N and Colombo, Nicoletta and Wu, Xiaohua and Sehouli, Jalid and Cruz, Felipe and Cibula, David and Monk, Bradley J and Nyvang, Gitte-Bettina and Friedlander, Michael and Lorusso, Domenica and Van Nieuwenhuysen, Els and Malik, Rozita and Glasspool, Rosalind and Marth, Christian and Leary, Alexandra and Cortés-Salgado, Alfonso and Zamagni, Claudio and Marmé, Frederik and Sufliarsky, Jozef and Hinson, Patsy and Zuradelli, Monica and Wang, Craig and Su, Fei and Paule, Ines and Miller, Michelle and Matulonis, Ursula A and González-Martín, Antonio},
title = {Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation},
journal = {Journal of Clinical Oncology},
year = {2025},
doi = {10.1200/jco-25-00225}
}
EUVIMED